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Abstract: Quinolin-8-yl 4-methyl-3-(piperidine-1-sulfonyl)benzoate (QMPSB) and quinolin-8-yl 4-
methyl-3-(piperidine-1-carbonyl)benzoate (QMPCB, SGT-11) are synthetic cannabinoid receptor
agonists (SCRAs). Knowing their metabolic fate is crucial for the identification of toxicological
screening targets and to predict possible drug interactions. The presented study aimed to identify
the in vitro phase I/II metabolites of QMPSB and QMPCB and to study the contribution of different
monooxygenases and human carboxylesterases by using pooled human liver S9 fraction (pHLS9), re-
combinant human monooxygenases, three recombinant human carboxylesterases, and pooled human
liver microsomes. Analyses were carried out by liquid chromatography high-resolution tandem mass
spectrometry. QMPSB and QMPCB showed ester hydrolysis, and hydroxy and carboxylic acid prod-
ucts were detected in both cases. Mono/dihydroxy metabolites were formed, as were corresponding
glucuronides and sulfates. Most of the metabolites could be detected in positive ionization mode with
the exception of some QMPSB metabolites, which could only be found in negative mode. Monooxy-
genase activity screening revealed that CYP2B6/CYP2C8/CYP2C9/CYP2C19/CYP3A4/CYP3A5
were involved in hydroxylations. Esterase screening showed the involvement of all investigated
isoforms. Additionally, extensive non-enzymatic ester hydrolysis was observed. Considering the
results of the in vitro experiments, inclusion of the ester hydrolysis products and their glucuronides
and monohydroxy metabolites into toxicological screening procedures is recommended.
Keywords: QMPSB; QMPCB; synthetic cannabinoid receptor agonists; SCRA; NPS; metabolism;
LC-HRMS/MS
1. Introduction
Synthetic cannabinoids, also known as synthetic cannabinoid receptor agonists (SCRAs),
represent one of the largest groups of the so-called new psychoactive substances (NPSs) [1,2].
SCRAs are often sold on the drug market after being sprayed on plant material [3]. Contin-
uous changes in the chemical structures lead to a continuous introduction of new SCRAs in
an attempt to circumvent legislation [3]. Even though the number of new SCRAs detected
annually in the EU decreased in recent years, they continue to represent an important
group of newly occurring NPSs alongside cathinones and opioids [2].
In 2007, quinolin-8-yl 4-methyl-3-(piperidine-1-sulfonyl)benzoate (QMPSB) was identi-
fied as a potent SCRA as a result of a high-throughput screening [4]. Further investigations
revealed that QMPSB is a potent full agonist at the CB1 and CB2 receptors with moderate
selectivity for the CB2 receptor [4,5]. In Queensland (Australia), QMPSB was found in a
large number of plant materials seized in 2011 and 2012 and published in 2016 [6]. QMPSB
was also the template for a new group of SCRAs based on a sulfamoyl benzoate structure
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and/or a quinolin-8-yl ester head group. In 2012, the company Stargate International
started research on this new SCRA group which included the amide analog of QMPSB,
quinolin-8-yl 4-methyl-3-(piperidine-1-carbonyl)benzoate (QMPCB, SGT-11). Chemical
structures of QMPSB and QMPCB can be found in Figure 1. By replacing the sulfamoyl
tail group linker with a carbonyl linker, the influence of the linker group on the phar-
macological properties was further investigated. However, tests on human volunteers
showed that the amide analog QMPCB had a lower potency than QMPSB [7]. Further
structural modifications led to a combination of the quinolin-8-yl ester head group with
an N-alkyl-1H-indole core, which resulted in the development and appearance of PB-22
(QUPIC), and BB-22 (QUCHIC) amongst others [7,8].
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In the context of cli ical a f rensic toxicology, data on the etabolism of e erging
PSs are i portant, particularly for e el i l tic l s ree i r c res i ri .
To our l t on the metabolism of QMPSB and QMPCB are v ilable in
the literature. Therefore, the aim of the study was to identify the etabolites -
stances as otential targets for t xicological screenings by liquid chro atography coupled
to high-resolution tandem mass spectrometry (LC-HRMS/ S). In vitro incubations using
pooled human liver S9 fraction (pHLS9) were performed to identify phase I and II metabo-
lites. Incubations with pHLS9 have been shown to generate the main human metabolites
co pared to hu an pri ary hepatocytes and are therefore appropriate alternatives to
incubations ith hu an pri ary hepatocytes [9].
An in vitro monooxygenase activity assay should clarify the involvement of individual
monooxygenases in the initial metabolic steps. Due to the instability of the ester bond
already described in the literature [5,6], the additional influence of human esterases on
ester hydrolysis was investigated.
2. Results and Discussion
2.1. Identification of In Vitro Phase I and II Metabolites of QMPSB
For metabolite identification, exact protonated or deprotonated precursor ion (PI)
masses of expected phase I and II metabolites were calculated. High-resolution full scan
data were examined for these masses and the corresponding MS2 spectra were interpreted.
Deviations between measured and calculated PI mass were only accepted up to 5 ppm. All
metabolites were tentatively identified since no reference material was available.
In total, 17 phase I and 4 phase II QMPSB metabolites were identified in pHLS9 or CYP
isozyme incubations (metabolites SM1–SM21; Table S1 in the Electronic Supplementary
Material, ESM). The ionization mode (positive or negative) and the incubation type (pHLS9
or CYP isozyme incubation) in which the respective metabolite was found are listed in
Table S1 (ESM).
Metabolites 2021, 11, 509 3 of 14
Nine metabolites were identified in pHLS9 incubations, which were ester hydrolysis
products and metabolites derived therefrom. No metabolite with an intact ester moiety
was found. It is important to mention that the ester hydrolysis products (SM9 and SM18
in Table S1) were also detectable in negative control samples without pHLS9 with an
abundant signal. This indicates that a rapid non-enzymatic ester hydrolysis took place.
The MS2 spectra of QMPSB and most abundant metabolites of pHLS9 incubation are given
in Figure 2A–F. Chromatograms of these compounds are shown in Figure S1 (ESM). MS2
spectra of further metabolites can be found in Figure S3 (ESM). The obtained MS2 spectrum
of QMPSB (Figure 2A) is comparable with data reported previously [6,7]. The base peak is
formed by the benzoyl ion with m/z 266.0845 (C13H16O3NS) after ester cleavage. Further
loss of the piperidine ring leads to fragment ion (FI) at m/z 183.0110 (C8H7O3S), followed by
loss of SO2 and CO, represented by the FIs at m/z 119.0491 (C8H7O) and m/z 91.0542 (C7H7).
Ester hydrolysis forms metabolite SM9 (Figure 2B) with protonated PI at m/z 282.0806
(C13H16O4NS). Loss of CO2 and 4-methyl benzoate resulted in the FIs at m/z 238.0907
(C12H16O2NS) and m/z 148.0438 (C5H10O2NS). SM12 (Figure 2C) with PI at m/z 298.0755
(C13H16O5NS) appears to be hydroxylated at the piperidine ring which is indicated by
the FI at m/z 155.0172 (C7H7O2S) obtained after the loss of CO2 and the hydroxylated
piperidine ring. Metabolite SM16 (Figure 2D) with PI at m/z 458.1126 (C19H24O10NS) is the
glucuronidated ester hydrolysis product indicated by the two most abundant FIs at m/z
282.0806 (C13H16O4NS) and m/z 148.0438 (C5H10O2NS), which were the most abundant
signals in the spectrum of the non-glucuronidated metabolite SM9. The ester hydrolysis
product 8-hydroxyquinoline (SM18 in Figure 2E) with PI at m/z 146.0600 (C9H8ON) shows
a loss of CO resulting in the FI at m/z 118.0651 (C8H8N). Metabolite SM21 (Figure 2F),
the glucuronidated 8-hydroxyquinoline, is characterized by FI at m/z 146.0600 (C9H8ON),
which corresponds to the PI of SM18 in Figure 2E. The MS2 spectra of further metabolites
are given in Figure S3 (ESM).
Due to the expected ester hydrolysis products with carboxylic acid function, HRMS/MS
analysis was also carried out in negative ionization mode. In fact, the majority of metabo-
lites derived from the carboxylic acid part after ester hydrolysis (SM10, SM11, SM12, SM13,
SM14, SM15, and SM16 in Table S1) were only detected with negative ionization. Therefore,
the use of negative ionization mode in addition to positive ionization mode can increase
the detectability of QMPSB metabolites and should be recommended when developing
screening strategies.
2.2. Identification of In Vitro Phase I and II Metabolites of QMPCB
In total, 30 phase I and 4 phase II metabolites of QMPCB were tentatively identified
in pHLS9 or CYP isozyme incubations (CM1–CM34). The ionization mode (positive
or negative) and the incubation type (pHLS9 or CYP isozyme incubation) in which the
respective metabolite was found are listed in Table S2 (ESM).
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Nine metabolites were identified in pHLS9 incubations. Similar to the pHLS9 incu-
bation results of QMPSB, all metabolites were ester hydrolysis products and metabolites
derived therefrom. Ester hydrolysis products were also found in control samples without
pHLS9 with an abundant signal, which indicated that non-enzymatic hydrolysis of QM-
PCB occurred, comparable to QMPSB. The MS2 spectra of QMPCB and most abundant
metabolites formed in pHLS9 incubation are depicted in Figure 3A–F. Chromatograms of
these compounds are shown in Figure S2 (ESM). MS2 spectra of additional metabolites
can be found in Figure S4 (ESM). The obtained MS2 spectrum of QMPCB (Figure 3A) is
comparable with data reported in a previous publication [7]. As with QMPSB, the base
peak is formed by the benzoyl ion at m/z 230.1176 (C14H16O2N) after ester cleavage. Fur-
ther cleavage of the amide bond leads to the FI at m/z 145.0284 (C9H5O2), followed by
two losses of CO, represented by the FIs at m/z 117.0335 (C8H5O) and m/z 89.0386 (C7H5).
Ester hydrolysis forms metabolite CM18 (Figure 3B) with protonated PI at m/z 248.1281
(C14H18O3N). Loss of piperidine resulting in FI at m/z 163.0390 (C9H7O3). FIs at m/z 69.0699
(C5H9) and m/z 112.0757 (C6H10ON) are caused by the alkyl chain of piperidine with and
without amide group. Metabolite CM23 (Figure 3C) with PI at m/z 264.1230 (C14H18O4N)
appears to be hydroxylated at the piperidine ring, which is indicated by the FI at m/z
163.0390 (C9H7O3). Metabolite CM29 (Figure 3D) with PI at m/z 424.1602 (C20H26O9N) is
the glucuronide of metabolite CM18, resulting in the FIs at m/z 248.1281 (C14H18O3N) and
m/z 163.0390 (C9H7O3), which are also the most abundant fragments of CM18. The ester
hydrolysis product 8-hydroxyquinoline was found as metabolite CM30 (Figure 3E). CM30
and the derived glucuronide (CM33 in Figure 3F) are also metabolites of QMPSB (SM18
and SM21) and have already been described there. MS2 spectra data of further metabolites
are given in Figure S4 (ESM).
Almost all QMPCB metabolites were detected in positive ionization mode (Table S2).
CM27 and CM28, two dihydroxy metabolites of the carboxylic acid product after ester
hydrolysis, were only detectable in negative ionization mode. Improvement in detectability
of the metabolites due to the additional negative ionization mode seemed to be of minor
importance in the case of QMPCB compared to QMPSB.
2.3. Proposed Metabolic Pathways of QMPSB
The proposed metabolic pathways are shown in Figure 4. For in vitro metabolism
of QMPSB, ester hydrolysis has been revealed to be an important step. Therefore, the
identified metabolites were sorted into three groups: metabolites with intact ester group
(SM1–SM8 in Figure 4), and the two ester hydrolysis products with additional metabolic
reactions: carboxylic acid part (SM9–SM17 in Figure 4) and 8-hydroxyquinoline (SM18–
SM21 in Figure 4). All metabolites with an intact ester group (SM1–SM8 in Figure 4), as well
as SM10, SM13, SM14, and SM19 (in Figure 4), were only identified in CYP incubations, not
in pHLS9 incubation. The reason for these findings could be that the phase I metabolites
formed during the pHLS9 incubation were further metabolized to phase II metabolites,
whereby the formed phase I metabolites were below the detection limit. In addition,
compared to CYP incubations, human carboxylesterases were present in pHLS9 incubations
and the incubation time was longer in pHLS9 incubations, which could have contributed
to increased ester hydrolysis. Therefore, pHLS9 metabolites are expected to have more
pronounced in vivo relevance than the metabolites that were additionally detected in the
recombinant CYP isozyme incubations. For the SCRA FUB-PB-22, which also contains
a quinolin-8-yl ester head group but an N-alkyl-1H-indole core, metabolites found in
authentic urine samples were described in the literature, and neither the parent drug nor
metabolites with intact ester were found [10].
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Starting from the carboxylic acid after ester hydrolysis (SM9 in Figure 4), three mono-
hydroxy metabolites could be found: SM13, which is hydroxylated at the 4-methylbenzoate
core, and SM12 and SM14 (Figure 4), which are hydroxylated at the piperidine ring. The
exact position of the hydroxy group on the core or piperidine cannot be determined from
the fragmentation. After the elimination of water, the dehydro metabolite SM11 (Figure 4)
was formed with a double bond at the piperidine ring (the exact position in the ring is
unknown). It should also be noted that a potential hydroxylation at the α-position to the
nitrogen atom of the piperidine ring could lead to ring-opening. This mechanism was
already described in the literature for other substances [11,12]. Further metabolic steps,
however, can lead to cleavage of the C5 alkyl chain of piperidine, which could be detected
with the metabolite SM10 (Figure 4). A dihydroxy metabolite was also found (SM15). In
phase II metabolism of the carboxylic acid part, the glucuronides of the metabolites SM9
and SM15 could be detected: SM16 and SM17 (Figure 4).
8-Hydroxyquinoline (SM18 in Figure 4) was found to be hydroxylated (SM19 in
Figure 4), although the exact position of the hydroxy group cannot be identified. In phase
II metabolism, sulfation (SM20 in Figure 4) and glucuronidation (SM21 in Figure 4) of
8-hydroxyquinoline could be detected. The metabolites SM19 and SM20 have already been
described in previous studies involving related SCRAs [9,10].
In pHLS9 incubations, the ester hydrolysis products SM9 and SM18 (Figure 4) as
well as their glucuronides SM16 and SM21 (Figure 4) and the monohydroxy metabolite
SM12 (Figure 4) showed the most abundant signals. Therefore, these metabolites are
suggested as main targets for toxicological screenings. However, it is important to note that
8-hydroxyquinoline (SM18) and metabolites derived from it are not specific metabolites of
QMPSB, but they can provide a hint for an SCRA with this partial structure.
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2.4. Proposed Metabolic Pathways of QMPCB
The proposed metabolic pathways of QMPCB are depicted in Figure 5. During the
in vitro metabolism of QMPCB, similar to QMPSB, ester hydrolysis played an important
role. Therefore, the metabolites were also sorted into three groups: metabolites with
an intact ester group (CM1–CM17 in Figure 5) and the two ester hydrolysis products
with additional metabolic reactions: carboxylic acid part (CM18–CM29 in Figure 5) and
8-hydroxyquinoline (CM30–CM34 in Figure 5). Similar to QMPSB, all QMPCB metabolites
with an intact ester group (CM1–CM17 in Figure 5) were only identified in CYP incubations.
These findings confirm the instability of the ester bond with 8-hydroxyquinoline under
pHLS9 incubation conditions. Some metabolites originating from ester hydrolysis could
only be detected in CYP incubations: CM19–CM22, CM24, CM26, CM27, and CM31
(Figure 5). These metabolites are predominantly the result of a combination of different
metabolic reactions, such as dihydroxylation or hydroxylation plus dehydrogenation. The
reasons for these results are given in Section 2.3. MS2 spectra of these metabolites are given
in Figure S4 (ESM).
Starting from the carboxylic acid part after ester hydrolysis, three monohydroxy
metabolites could be found similar to QMPSB: CM23, CM24, and CM25 (Figure 5). In all
three metabolites, the hydroxyl group is located on the piperidine ring. A ring-opening of
the piperidine after hydroxylation at the α-position to the nitrogen atom of the piperidine
ring [11,12] could also take place in the QMPCB, as already described above for QMPSB. The
N,N-dealkyl metabolite could also be found (CM19 in Figure 5). In the case of the dihydroxy
metabolites, the 4-methylbenzoate core and piperidine ring were hydroxylated (CM26 in
Figure 5), or the piperidine ring was hydroxylated twice (CM27/CM28 in Figure 5). During
phase II metabolism, the glucuronide of the carboxylic acid part following ester hydrolysis
could be found analogous to QMPSB metabolism.
8-Hydroxyquinoline (CM30 in Figure 5) and the corresponding monohydroxy (CM31
in Figure 5), sulfate (CM32 in Figure 5), and glucuronide metabolites (CM33 in Figure 5)
could also be found, which paralleled the observations made from QMPSB incubations.
In addition, the glucuronide of the monohydroxy metabolite (CM34 in Figure 5) could
be detected.
In pHLS9 incubations, the ester hydrolysis products CM18 and CM30 (Figure 5) as
well as their glucuronides CM29 and CM33 (Figure 5) and two monohydroxy metabolites
CM23 and CM25 (Figure 5) showed the most abundant signals. Therefore, these metabolites
are suggested as main targets for toxicological screenings. As already mentioned with
QMPSB, 8-hydroxyquinoline (CM30 in Figure 5) and metabolites derived from it are not
specific metabolites of QMPCB, but they can provide an indication for a SCRA with this
partial structure.
2.5. Monooxygenase Activity Screening of QMPSB and QMPCB
The monooxygenase activity screening revealed the involvement of several monooxy-
genases in the metabolism of QMPSB and QMPCB (Tables S3 and S4 in the ESM). CYP2B6,
CYP2C8, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 were involved in most metabolic
reactions of both SCRAs. Although the quantitative involvement of each isoform was
no investigated, it is quite unlikely that a drug-drug interaction causing the inhibition
of a single CYP isozyme will lead to a significant change in hepatic clearance given that
several isoforms were involved. The same can be assumed for poor metabolizers of single
CYP isozymes.
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2.6. Esterases Activity Screening with Recombinant hCES1b, hCES1c, hCES2, pHLM, and pHLS9
QMPSB and QMPCB both contain a quinolin-8-yl ester head group. According to
previous reports, the chemical instability of this ester head group was already described
in form of hydrolysis [5] and trans-esterification with solvents such as methanol and
ethanol [6]. This must be considered when extracting them from seized plant material or
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human samples like plasma or urine. To avoid trans-esterification during storage, the stock
solution for all experiments was therefore made with acetonitrile instead of methanol.
Different human carboxylesterase (hCES) isoforms catalyze the hydrolysis of ester-
containing drugs [13,14]. The isoforms hCES1b and hCES1c are primarily expressed in
the liver, and hCES2 is mainly expressed in the gastrointestinal tract [13]. In addition to
the recombinant isoforms, the substrates were incubated with pHLM and pHLS9, which
represent the natural hCES spectrum of the human liver. Negative control incubations
(without enzyme) were conducted to evaluate non-enzymatic ester hydrolysis.
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These findings indicate that ester hydrolysis plays an important role in phase I
metabolism of QMPSB and QMPCB. During sampling and handling, the non-enzymatic
ester degradation should always be taken into account. To reduce substrate degradation,
both SCRAs should be kept in solvents that cannot cause hydrolysis or transesterification.
3. Materials and Methods
3.1. Chemicals and Reagents
QMPSB and QMPCB were obtained from the library of Stargate International (Auck-
land, New Zealand) [7]. Stock solutions of QMPSB and QMPCB were prepared in acetoni-
trile (1 mg/mL) and stored at−18 ◦C. Trimipramine-d3 was obtained from LGC (Wesel, Ger-
many). Isocitrate, isocitrate dehydrogenase, superoxide dismutase, 3′-phosphoadenosine-
5′phosphosulfate (PAPS), S-(5′-adenosyl)-L-methionine (SAM), dithiothreitol, reduced
glutathione, acetyl coenzyme A, magnesium chloride (MgCl2), potassium dihydrogen
phosphate (KH2PO4), dipotassium hydrogen phosphate (K2HPO4), and Tris hydrochloride
were obtained from Sigma-Aldrich (Taufkirchen, Germany). NADP+ was from Biomol
(Hamburg, Germany). Baculovirus-infected insect cell microsomes (Supersomes) con-
taining the human cDNA-expressed cytochrome P450 isozymes CYP1A2 (1 nmol/mL),
CYP2A6 (2 nmol/mL), CYP2B6 (1 nmol/mL), CYP2C8 (1 nmol/mL), CYP2C9 (2 nmol/mL),
CYP2C19 (1 nmol/mL), CYP2D6 (1 nmol/mL), CYP2E1 (2 nmol/mL), CYP3A4 (1 nmol/mL),
CYP3A5 (1 nmol/mL), or flavin-containing monooxygenase 3 (FMO3, 5 mg/mL), as well
as pooled human liver microsomes (pHLM, 20 mg protein/mL, 360 pmol total CYP/mg,
26 donors), pHLS9 (20 mg protein/mL, 8 donors), recombinant human carboxylesterase
hCES1b (5 mg/mL), hCES1c (5 mg/mL), hCES2 (5 mg/mL), UGT reaction mixture solution
A (25 mM UDP-glucuronic acid), and UGT reaction mixture solution B (250 mM Tris HCl,
40 mM MgCl2, and 125 µg alamethicin/mL) were obtained from Corning (Amsterdam,
The Netherlands). After delivery, the enzymes were thawed at 37 ◦C, aliquoted, snap-
frozen in liquid nitrogen, and stored at −80 ◦C until use. Acetonitrile (LC-MS grade),
methanol (LC-MS grade), ammonium formate (analytical grade), formic acid (LC-MS
grade), and all other reagents and chemicals (analytical grade) were bought from VWR
(Darmstadt, Germany).
3.2. pHLS9 Incubations for Investigation of Phase I and II Metabolites
Incubations with pHLS9 were conducted in accordance with an earlier publication
with minor modifications [9]. First, a solution with pHLS9 (2 mg protein/mL), 0.1 mM
acetyl coenzyme A, 25 µg/mL alamethicin (UGT reaction mixture solution B), 90 mM
phosphate buffer (pH 7.4), 2.5 mM Mg2+, 2.5 mM isocitrate, 0.6 mM NADP+, 0.9 U/mL
isocitrate dehydrogenase, and 100 U/mL superoxide dismutase was preincubated for
10 min at 37 ◦C. After preincubation, 2.5 mM UDP-glucuronic acid (UGT reaction mixture
solution A), 40 µM PAPS, 1.2 mM SAM, 1 mM dithiothreitol, 10 mM glutathione, and
25 µM QMPSB or QMPCB were added. All given concentrations are concentrations in the
final incubation mixture (final incubation volume: 150 µL). The total amount of organic
solvent in the incubations was less than 2% [16].
Reactions were started by adding the substrate (QMPSB or QMPCB). The duration
of the incubation was set to six hours at 37 ◦C, with a 60 µL aliquot being taken after
one hour.
The reactions of the aliquot were terminated by adding 20 µL ice-cold acetonitrile
containing 2.5 µM trimipramine-d3 as internal standard (IS). After 360 min, metabolic
reactions in the remaining incubation solution were terminated by the addition of 30 µL ice-
cold acetonitrile containing 2.5 µM trimipramine-d3. All samples were cooled for 30 min
at −20 ◦C and centrifuged at 18,407× g for 2 min. The supernatants were transferred
to autosampler vials and analyzed using LC-HRMS/MS. Blank incubations (without
substrate) and negative control incubations (without pHLS9) were carried out to confirm
the absence of interfering and non-metabolically formed compounds. All incubations were
performed in duplicates (n = 2).
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3.3. Monooxygenase Activity Screening
Incubations with monooxygenases were performed in accordance with a previous
study with minor modifications [17]. QMPSB or QMPCB (25 µM each) was incubated
with CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4,
CYP3A5 (50 pmol/mL each), or FMO3 (0.25 mg protein/mL), as well as 90 mM phosphate
buffer (pH 7.4), 5 mM Mg2+, 5 mM isocitrate, 1.2 mM NADP+, 0.5 U/mL isocitrate de-
hydrogenase, and 200 U/mL superoxide dismutase, for 30 min at 37 ◦C. For incubations
with CYP2A6 and CYP2C9, 90 mM Tris buffer (pH 7.4) was used instead of phosphate
buffer, according to the recommendations of the manufacturer. All given concentrations are
concentrations in the final incubation mixture (final incubation volume: 50 µL). Reactions
were started by adding the substrate (QMPSB or QMPCB). After 30 min, reactions were
terminated by adding 50 µL of ice-cold acetonitrile containing 2.5 µM trimipramine-d3.
The samples were centrifuged at 18,407× g for 2 min, and the supernatants were trans-
ferred to autosampler vials, and analyzed using LC-HRMS/MS. A negative control sample
(without enzyme) was incubated to identify non-metabolically formed compounds. Fur-
thermore, pHLM (1 mg/mL) positive control samples were incubated. All incubations
were performed in duplicates (n = 2).
3.4. Esterase Activity Screening with Recombinant hCES1b, hCES1c, hCES2, pHLM, and pHLS9
Incubations with esterases were carried out as described in a previous publication
with minor modifications [18]. QMPSB and QMPCB (10 µM final concentration) were
incubated with hCES1b, hCES1c, hCES2 (0.2 µg/µL final concentration each), pHLM,
and pHLS9 (2 µg/µL final concentration each) in phosphate buffer 100 mM pH 7.4 for
60 min at 37 ◦C. The total volume of the incubations was 150 µL. The incubations were
started by adding the substrates. Negative control incubations (without enzyme) were
conducted to evaluate non-enzymatic ester hydrolysis. At 0 and 60 min, 40 µL samples
were taken. These samples were stopped immediately with 120 µL ice-cold acetonitrile
containing trimipramine-d3 (2.5 µM). After centrifugation for 2 min at 18,407× g, 50 µL of
the supernatant was transferred to an autosampler vial, and analyzed using LC-HRMS/MS.
All incubations were performed in duplicates (n = 2).
3.5. LC-HRMS/MS Settings
A Thermo Fisher Scientific (TF, Dreieich, Germany) Dionex UltiMate 3000 RS LC
system consisting of a degasser, a quaternary pump, and an HTC PAL autosampler (CTC
Analytics AG, Zwingen, Switzerland) coupled to a TF Q-Exactive mass spectrometer with
heated electrospray ionization (HESI)-II source was used. An external mass calibration
was done prior to analysis according to the manufacturer’s recommendations. An injection
volume of 5 µL was used for all samples. Gradient elution was implemented on a TF
Accucore Phenyl-Hexyl column (100 mm × 2.1 mm, 2.6 µm) at 40 ◦C in accordance
with previous work [19]. The mobile phases for gradient elution consisted of 2 mM
aqueous ammonium formate containing formic acid (0.1%, v/v, pH 3, eluent A) and 2 mM
ammonium formate solution with acetonitrile:methanol (1:1, v/v), water (1%, v/v), and
formic acid (0.1%, v/v, eluent B). The following gradient settings were used: 0–1 min
hold 99% A, 1–10 min to 1% A, 10–11.5 min hold 1% A, and 11.5–13.5 min hold 99% A.
The flow rate was 500 µL/min (0–10 min) and 800 µL/min (10–13.5 min). The following
HESI-II source settings were used: heater temperature, 320 ◦C; ion transfer capillary
temperature, 320 ◦C; spray voltage, 4.0 kV; ionization mode, positive or negative; sheath
gas, 60 arbitrary units (AU); auxiliary gas, 10 AU; sweep gas, 0 AU; S-lens RF level, 60.0.
Mass spectrometry was carried out in full scan mode with subsequent data-dependent
acquisition of MS2 (ddMS2) with priority to mass to charge ratios (m/z) of the parent
compound and expected metabolites. The following full scan data acquisition settings
were used: resolution, 35,000 FWHM at m/z 200; microscans, 1; automatic gain control
(AGC) target, 1E6; maximum injection time (maxIT), 120 ms; scan range, m/z 80–850. An
inclusion list containing m/z values of QMPSB or QMPCB and of expected metabolites such
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as hydrolysis products, dealkyl and hydroxy metabolites (phase I), as well as sulfates, and
glucuronides (phase II), was used for ddMS2 mode. The following ddMS2 mode settings
were used: option “pick others”, enabled; dynamic exclusion, feature not used; resolution,
17,500 FWHM at m/z 200; microscans, 1; isolation window, m/z 1.0; loop count, 5; AGC
target, 2E5; maxIT, 250 ms; high collision dissociation cell with stepped normalized collision
energy, 17.5, 35.0, 52.5; exclude isotopes, on; spectrum data type, profile. ChemSketch
2020.1.1 (ACD/Labs, Toronto, Canada) was used to draw chemical structures of QMPSB,
QMPCB, and their expected metabolites, and to calculate the exact masses. TF Xcalibur
Qual Browser 4.1.31.9 was used for MS data analysis.
4. Conclusions
In total, 21 metabolites of QMPSB and 34 metabolites of QMPCB were tentatively
identified using in vitro tools. All three tested human carboxylesterase isoforms (hCES1b,
hCES1c, and hCES2) catalyzed the hydrolysis. The esterase activity screening also revealed
a rapid non-enzymatic ester hydrolysis of both compounds. It is thus questionable, whether
metabolites with an intact ester bond might be detectable in toxicological screenings. The
ester hydrolysis products and their glucuronides and monohydroxy metabolites are thus
recommended as targets for toxicological screenings for both substances. In the case
of QMPSB, some of these targets could only be detected in negative ionization mode.
Therefore, negative ionization mode is recommended for appropriate screenings. Different
CYP isoforms were involved in the phase I metabolism of both substances, mainly CYP2B6,
CYP2C8, CYP2C9, CYP2C19, CYP3A4, and CYP3A5. Due to the involvement of several
CYP isozymes, the inhibition of a single CYP isozyme by a drug-drug interaction is unlikely
to have a significant effect on hepatic clearance.
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